BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 19878873)

  • 1. Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase.
    Zhang Q; Gu J; Li L; Liu J; Luo B; Cheung HW; Boehm JS; Ni M; Geisen C; Root DE; Polyak K; Brown M; Richardson AL; Hahn WC; Kaelin WG; Bommi-Reddy A
    Cancer Cell; 2009 Nov; 16(5):413-24. PubMed ID: 19878873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Edging toward new therapeutics with cyclin D1 Egl'ng on cancer.
    Dang CV
    Cancer Cell; 2009 Nov; 16(5):361-2. PubMed ID: 19878865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron chelation and 2-oxoglutarate-dependent dioxygenase inhibition suppress mantle cell lymphoma's cyclin D1.
    Babosova O; Kapralova K; Raskova Kafkova L; Korinek V; Divoky V; Prchal JT; Lanikova L
    J Cell Mol Med; 2019 Nov; 23(11):7785-7795. PubMed ID: 31517438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase.
    Zheng X; Zhai B; Koivunen P; Shin SJ; Lu G; Liu J; Geisen C; Chakraborty AA; Moslehi JJ; Smalley DM; Wei X; Chen X; Chen Z; Beres JM; Zhang J; Tsao JL; Brenner MC; Zhang Y; Fan C; DePinho RA; Paik J; Gygi SP; Kaelin WG; Zhang Q
    Genes Dev; 2014 Jul; 28(13):1429-44. PubMed ID: 24990963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EglN2 contributes to triple negative breast tumorigenesis by functioning as a substrate for the FBW7 tumor suppressor.
    Takada M; Zhuang M; Inuzuka H; Zhang J; Zurlo G; Zhang J; Zhang Q
    Oncotarget; 2017 Jan; 8(4):6787-6795. PubMed ID: 28036276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatic pairing of chromosome 19 in renal oncocytoma is associated with deregulated EGLN2-mediated [corrected] oxygen-sensing response.
    Koeman JM; Russell RC; Tan MH; Petillo D; Westphal M; Koelzer K; Metcalf JL; Zhang Z; Matsuda D; Dykema KJ; Houseman HL; Kort EJ; Furge LL; Kahnoski RJ; Richard S; Vieillefond A; Swiatek PJ; Teh BT; Ohh M; Furge KA
    PLoS Genet; 2008 Sep; 4(9):e1000176. PubMed ID: 18773095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolyl-4-hydroxylase PHD2- and hypoxia-inducible factor 2-dependent regulation of amphiregulin contributes to breast tumorigenesis.
    Bordoli MR; Stiehl DP; Borsig L; Kristiansen G; Hausladen S; Schraml P; Wenger RH; Camenisch G
    Oncogene; 2011 Feb; 30(5):548-60. PubMed ID: 20856199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expressions of individual PHDs associate with good prognostic factors and increased proliferation in breast cancer patients.
    Peurala E; Koivunen P; Bloigu R; Haapasaari KM; Jukkola-Vuorinen A
    Breast Cancer Res Treat; 2012 May; 133(1):179-88. PubMed ID: 21877141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein kinase C beta enhances growth and expression of cyclin D1 in human breast cancer cells.
    Li H; Weinstein IB
    Cancer Res; 2006 Dec; 66(23):11399-408. PubMed ID: 17145886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The multifaceted role of EGLN family prolyl hydroxylases in cancer: going beyond HIF regulation.
    Strocchi S; Reggiani F; Gobbi G; Ciarrocchi A; Sancisi V
    Oncogene; 2022 Jul; 41(29):3665-3679. PubMed ID: 35705735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer.
    Cohen B; Shimizu M; Izrailit J; Ng NF; Buchman Y; Pan JG; Dering J; Reedijk M
    Breast Cancer Res Treat; 2010 Aug; 123(1):113-24. PubMed ID: 19915977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
    Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM
    BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolyl-4-hydroxylase α subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition.
    Xiong G; Deng L; Zhu J; Rychahou PG; Xu R
    BMC Cancer; 2014 Jan; 14():1. PubMed ID: 24383403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L-Mimosine blocks cell proliferation via upregulation of B-cell translocation gene 2 and N-myc downstream regulated gene 1 in prostate carcinoma cells.
    Chung LC; Tsui KH; Feng TH; Lee SL; Chang PL; Juang HH
    Am J Physiol Cell Physiol; 2012 Feb; 302(4):C676-85. PubMed ID: 22116304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AIB1 sequestration by androgen receptor inhibits estrogen-dependent cyclin D1 expression in breast cancer cells.
    De Amicis F; Chiodo C; Morelli C; Casaburi I; Marsico S; Bruno R; Sisci D; Andò S; Lanzino M
    BMC Cancer; 2019 Nov; 19(1):1038. PubMed ID: 31684907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.
    Koivunen P; Lee S; Duncan CG; Lopez G; Lu G; Ramkissoon S; Losman JA; Joensuu P; Bergmann U; Gross S; Travins J; Weiss S; Looper R; Ligon KL; Verhaak RG; Yan H; Kaelin WG
    Nature; 2012 Feb; 483(7390):484-8. PubMed ID: 22343896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the role of the HIF hydroxylase family members in erythropoiesis.
    Fisher TS; Lira PD; Stock JL; Perregaux DG; Brissette WH; Ozolins TR; Li B
    Biochem Biophys Res Commun; 2009 Oct; 388(4):683-8. PubMed ID: 19683512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1-IRIS activates cyclin D1 expression in breast cancer cells by downregulating the JNK phosphatase DUSP3/VHR.
    Hao L; ElShamy WM
    Int J Cancer; 2007 Jul; 121(1):39-46. PubMed ID: 17278098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent deregulation of gelsolin and cyclin D1 in the majority of human and rodent breast cancers.
    Dong Y; Asch HL; Medina D; Ip C; Ip M; Guzman R; Asch BB
    Int J Cancer; 1999 Jun; 81(6):930-8. PubMed ID: 10362141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endogenous 2-oxoglutarate levels impact potencies of competitive HIF prolyl hydroxylase inhibitors.
    Thirstrup K; Christensen S; Møller HA; Ritzén A; Bergström AL; Sager TN; Jensen HS
    Pharmacol Res; 2011 Sep; 64(3):268-73. PubMed ID: 21504793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.